2020 ACTT-1 TRIAL Remdesivir for the Treatment of Covid-19 Double-blind, randomized, placebo-controlled trial Objective: To evaluate the clinical efficacy and safety of putative investigational therapeutic agent remdesivir among hospitalized adults with laboratory-confirmed Covid-19. M Patients with lab-confirmed SARS-CoV-2 infection 1,063 … Read More
Blog
ACTS Trial: Ascorbic acid, Steroids and Thiamine in Septic Shock
2020 ACTS TRIAL Effect of ascorbic acid, corticosteroids, and thiamine on organ injury in septic shock Multicenter, randomized, blinded, placebo-controlled superiority trial M Objective: To determine whether the combination of ascorbic acid, corticosteroids, and thiamine attenuates organ injury in patients … Read More
ACT Trial Summary: Acetylcysteine before Angiography
ACETYLCYSTEINE FOR PREVENTION OF RENAL OUTCOMES IN PATIENTS UNDERGOING ANGIOGRAPHY – ACT TRIAL Multicenter, Double-blind, Randomized, Placebo-controlled Trial STUDY OBJECTIVE: To Assess the use of acetylcysteine for preventing contrast-induced acute kidney injury in patients undergoing angiography 2308 Adults with ≥1 … Read More
ACTT-4 Trial Summary: Baricitinib in Covid-19
2022 ACTT-4 TRIAL Baricitinib versus dexamethasone for adults hospitalised with COVID-19 double-blind, double placebo-controlled, randomised controlled trial M Objective: To compare baricitinib in combination with remdesivir versus dexamethasone with remdesivir at preventing progression to mechanical ventilation or death 1010 patients … Read More
ACURASYS Trial Summary: NM blockers in ARDS
2010 ACURASYS TRIAL Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome Multicenter, double-blinded, placebo-controlled trial Objective: To assess if administration of cisatracurium improve survival when compared to placebo in ICU patients undergoing mechanical ventilation for early severe ARDS 340 patients … Read More
ADAM VTE Trial Summary: Apixaban in Cancer-associated VTE
2019 ADAM VTE TRIAL Apixaban and dalteparin in active malignancy-associated venous thromboembolism multicenter, randomized, open-label superiority trial 287 patients 0 Objective: To study side effects of and compare apixaban and dalteparin in reducing blood clots in patients with cancer-related VTE. … Read More
ADAPTABLE Trial Summary: Aspirin Dosing in CV Disease
2013 ADAPTABLE TRIAL Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease Open-label, pragmatic design, randomized controlled trial M Objective: To assess whether a strategy of aspirin 325 mg/day would result in a lower risk of death from any cause, hospitalization … Read More
ACTIVE W Trial Summary: Clopidogrel + ASA vs. OAC for Atrial Fibrillation
2006 ACTIVE W TRIAL Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation Randomized, open treatment, controlled trial M Objective: Among patients with nonvalvular AF, how does combination aspirin/clopidogrel compare to warfarin in reducing the incidence of stroke, systemic embolism, … Read More
ACTIVE A Trial Summary: Clopidogrel + Aspirin in Atrial Fibrillation
2009 ACTIVE A TRIAL Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation Multicenter, double-blind, parallel-group trial M Objective: To assess if the addition of clopidogrel to aspirin reduces the risk of vascular events compared to aspirin alone … Read More
ACTIV-4B Trial Summary: Antithrombotic Therapy in Covid-19
2021 ACTIV-4B TRIAL Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19 minimal-contact, adaptive, randomized, double-blind, placebo-controlled Objective: To assess whether anticoagulant or antiplatelet therapy can safely reduce major adverse cardiopulmonary outcomes among symptomatic but … Read More